| # | Title | Journal | Year | Citations |
|---|
| 1 | Intratumor Heterogeneity: Seeing the Wood for the Trees | Science Translational Medicine | 2012 | 443 |
| 2 | Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial | Lancet Oncology, The | 2017 | 415 |
| 3 | Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea‐predominant irritable bowel syndrome | Alimentary Pharmacology and Therapeutics | 2009 | 361 |
| 4 | Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction | Cancer Cell | 2015 | 299 |
| 5 | Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial | Annals of Oncology | 2015 | 271 |
| 6 | Optimising Cancer Vaccine Design in Sarcoma | Cancers | 2019 | 211 |
| 7 | Associations Between Breast Cancer Survivorship and Adverse Mental Health Outcomes: A Systematic Review | Journal of the National Cancer Institute | 2018 | 205 |
| 8 | Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study | Annals of Oncology | 2017 | 201 |
| 9 | New Strategies in Estrogen Receptor–Positive Breast Cancer | Clinical Cancer Research | 2010 | 191 |
| 10 | Review article: small intestinal bacterial overgrowth - prevalence, clinical features, current and developing diagnostic tests, and treatment | Alimentary Pharmacology and Therapeutics | 2013 | 171 |
| 11 | Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study | Annals of Oncology | 2008 | 163 |
| 12 | SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair | Oncogene | 2015 | 147 |
| 13 | Lapatinib: A novel EGFR/HER2 tyrosine kinase inhibitor for cancer | Drugs of Today | 2006 | 129 |
| 14 | The budgetary impact of 5-HT3 receptor antagonists in the management of chemotherapy-induced emesis | European Journal of Cancer | 1993 | 123 |
| 15 | A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer | Annals of Oncology | 1997 | 121 |
| 16 | Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer | British Journal of Cancer | 2017 | 118 |
| 17 | Treatment options for small cell lung cancer – do we have more choice? | British Journal of Cancer | 2010 | 104 |
| 18 | Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution | Nature Communications | 2015 | 100 |
| 19 | A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma | Annals of Oncology | 2013 | 98 |
| 20 | Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study | Annals of Oncology | 2017 | 94 |
| 21 | Postmenopausal estrogen synthesis and metabolism: Alterations caused by aromatase inhibitors used for the treatment of breast cancer | The Journal of Steroid Biochemistry | 1990 | 93 |
| 22 | Prognostic value of neutrophil-to-lymphocyte ratio in advanced oesophago-gastric cancer: exploratory analysis of the REAL-2 trial | Annals of Oncology | 2016 | 82 |
| 23 | International Association of Pancreatology (IAP)/European Pancreatic Club (EPC) consensus review of guidelines for the treatment of pancreatic cancer | Pancreatology | 2016 | 81 |
| 24 | Enhancing Endocrine Therapy for Hormone Receptor–Positive Advanced Breast Cancer: Cotargeting Signaling Pathways | Journal of the National Cancer Institute | 2015 | 79 |
| 25 | Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial | Annals of Oncology | 2013 | 76 |
| 26 | Global geriatric oncology: Achievements and challenges | Journal of Geriatric Oncology | 2017 | 76 |
| 27 | A modified inflammatory bowel disease questionnaire and the Vaizey Incontinence questionnaire are more sensitive measures of acute gastrointestinal toxicity during pelvic radiotherapy than RTOG grading | International Journal of Radiation Oncology Biology Physics | 2006 | 75 |
| 28 | Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial | Gastric Cancer | 2022 | 72 |
| 29 | Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey | European Journal of Cancer | 2018 | 69 |
| 30 | Development and validation of deep learning classifiers to detect Epstein-Barr virus and microsatellite instability status in gastric cancer: a retrospective multicentre cohort study | The Lancet Digital Health | 2021 | 69 |
| 31 | Effectiveness and tolerability of colesevelam hydrochloride for bile-acid malabsorption in patients with cancer: A retrospective chart review and patient questionnaire | Clinical Therapeutics | 2009 | 65 |
| 32 | Organ‐specific management and supportive care in chronic graft‐versus‐host disease | British Journal of Haematology | 2012 | 65 |
| 33 | Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial | Annals of Oncology | 2017 | 64 |
| 34 | Challenges and Opportunities in the Clinical Development of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma | Hepatology | 2019 | 64 |
| 35 | Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials | Annals of Oncology | 2018 | 61 |
| 36 | A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy | Breast Cancer Research and Treatment | 2008 | 60 |
| 37 | Opioid genetics: the key to personalized pain control? | Clinical Genetics | 2012 | 59 |
| 38 | Anti-tumour activity against B16-F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccine | Gene Therapy | 1999 | 58 |
| 39 | The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer | Annals of Oncology | 2015 | 58 |
| 40 | Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer | Annals of Oncology | 2016 | 58 |
| 41 | Retroconversion of immature teratoma of the ovary: CT appearances | Clinical Radiology | 1991 | 56 |
| 42 | Small bowel bacterial overgrowth and lactose intolerance during radical pelvic radiotherapy: An observational study | European Journal of Cancer | 2008 | 55 |
| 43 | Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer | Clinical Cancer Research | 2021 | 55 |
| 44 | Epigenetic regulation in RCC: opportunities for therapeutic intervention? | Nature Reviews Urology | 2012 | 51 |
| 45 | Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach | PLoS ONE | 2015 | 50 |
| 46 | Pneumonitis and pulmonary fibrosis associated with breast cancer treatments | Breast Cancer Research and Treatment | 2014 | 48 |
| 47 | Diffusion-weighted (DW) MRI in lung cancers: ADC test-retest repeatability | European Radiology | 2017 | 46 |
| 48 | Prevalence of COVID-19-related risk factors and risk of severe influenza outcomes in cancer survivors: A matched cohort study using linked English electronic health records data | EClinicalMedicine | 2020 | 45 |
| 49 | Use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in older patients with ER-positive HER2-negative breast cancer: Young International Society of Geriatric Oncology review paper | Therapeutic Advances in Medical Oncology | 2018 | 44 |
| 50 | Quality of life and mental health in breast cancer survivors compared with non-cancer controls: a study of patient-reported outcomes in the United Kingdom | Journal of Cancer Survivorship | 2021 | 44 |
